FOLH1 and prostate carcinoma: 68Ga-PSMA-PET/CT is established in the clinical routine of prostate cancer diagnostics and follow-up with studies showing an excellent sensitivity and specificity, especially in patients with biochemical recurrence, but also for therapy monitoring [1].